Tiantian Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tiantian Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Jixing Peng
Key Laboratory of Testing and Evaluation for Aquatic Product Safety and Quality, Ministry of Agriculture and Rural Affairs, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao 266071, China
1 shared publication - Ningning He
School of Basic Medicine, Qingdao Medical College, Qingdao University, Qingdao 266071, China
1 shared publication - Shangyong Li
School of Basic Medicine, Qingdao Medical College, Qingdao University
1 shared publication - Shuyin Yang
School of Basic Medicine, Qingdao Medical College, Qingdao University, Qingdao 266071, China
1 shared publication - Xinnan Zhao
Key Laboratory of Testing and Evaluation for Aquatic Product Safety and Quality, Ministry of Agriculture and Rural Affairs, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao 266071, China
1 shared publication - Yan Di
Key Laboratory of Testing and Evaluation for Aquatic Product Safety and Quality, Ministry of Agriculture and Rural Affairs, Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Qingdao 266071, China
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by MDPI AG in Marine Drugs
- Vol. 24 (8) , 281
Integrated Multi-Omics Analysis of Antarctic Krill Oil in Alleviating DSS-Induced Colitis and Modulating Gut Microbiota in Mice
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with elusive etiology and limited therapeutic options, accompanied by potential side effects. In this study, to investigate the therapeutic potential of Antarctic krill oil (AKO) in a dextran sulfate sodium (DSS)-induced mouse colitis model, animal experiments, molecular assays, transcriptomics, metabolomics, and 16S rRNA gene sequencing were conducted. Our results revealed that supplementation of AKO significantly alleviated colitis symptoms, such as weight loss, and inflammatory responses. Moreover, multi-omics analyses demonstrated that AKO inhibited the PI3K/Akt signaling pathway, remodeled beneficial gut microbiota, and reshaped metabolite profiles associated with glycerolphospholipid metabolism. Remarkably, AKO alleviated DSS-induced colitis, accompanied by coordinated changes in the gut microbiota, metabolites, and transcriptome, which were associated with suppression of key inflammatory pathways. These findings present experimental evidence for the potential of AKO as a marine-based nutritional intervention for UC, and offer novel perspectives on microbiota-targeted therapies for inflammatory diseases.
- 14 August 2026
- Published by MDPI AG in Marine Drugs
- Vol. 24 (8) , 281
Open AccessIntegrated Multi-Omics Analysis of Antarctic Krill Oil in Alleviating DSS-Induced Colitis and Modulating Gut Microbiota in Mice
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with elusive etiology and limited therapeutic options, accompanied by potential side effects. In this study, to investigate the therapeutic potential of Antarctic krill oil (AKO) in a dextran sulfate sodium (DSS)-induced mouse colitis model, animal experiments, molecular assays, transcriptomics, metabolomics, and 16S rRNA gene sequencing were conducted. Our results revealed that supplementation of AKO significantly alleviated colitis symptoms, such as weight loss, and inflammatory responses. Moreover, multi-omics analyses demonstrated that AKO inhibited the PI3K/Akt signaling pathway, remodeled beneficial gut microbiota, and reshaped metabolite profiles associated with glycerolphospholipid metabolism. Remarkably, AKO alleviated DSS-induced colitis, accompanied by coordinated changes in the gut microbiota, metabolites, and transcriptome, which were associated with suppression of key inflammatory pathways. These findings present experimental evidence for the potential of AKO as a marine-based nutritional intervention for UC, and offer novel perspectives on microbiota-targeted therapies for inflammatory diseases.